14 jan: SUPER SUPPER I EN KOLD TID
18 jan: Udsigt til stærkt 1. halvår på aktiemarkederne
14-01-2011 17:02:34

Ad hoc reports in accordance with Sec. 15 of the German Securities Trading Act - Dräger increases net sales in 2010 by around 14 percent

Drägerwerk AG & Co. KGaA /

Ad hoc reports in accordance with Sec. 15 of the German Securities Trading Act -

Dräger increases net sales in 2010 by around 14 percent

Processed and transmitted by Thomson Reuters.

The issuer is solely responsible for the content of this announcement.

EBIT margin at the upper limit of the forecast 

According to preliminary estimates, Drägerwerk AG & Co. KGaA achieved net sales growth of around 14 percent and record net sales of EUR 2.2 billion in 2010 compared to EUR 1.9 billion in 2009. In October 2010, the company still anticipated net sales growth around 10 percent. The EBIT margin reached 8 to 9 percent, the upper limit of the 2010 forecast. Order intake rose by around 9 percent year on year to EUR 2.2 billion. 

The medical division recorded order intake of around 8 percent and generated net sales of EUR 1.5 billion - an increase of approximately 17 percent compared to the previous year. The EBIT margin was around 12 percent according to preliminary estimates. In the safety division, order intake went up by about 10 percent and net sales reached EUR 0.7 billion, corresponding to a rise of around 9 percent compared to 2009. The EBIT margin came to around 9 percent according to preliminary estimates. 

The reasons for the positive net sales and earnings development were the unexpectedly high order intake in the fourth quarter of 2010, continuous positive developments in the Americas and Asia/Pacific and favorable currency effects. The turnaround program also had an extremely positive effect. 

In 2011, Dräger will invest even larger sums into research and development, implement projects even more quickly and improve its marketing and sales organization in particular. For this reason, Dräger expects slightly higher group net sales in 2011 and an EBIT margin between 7.5 percent and 8.5 percent. The estimated development of net sales and margins in fiscal year 2011 is based on the assumption that the markets relevant to Dräger will continue their steady development and that exchange rates will remain at the current level. In the medium term, the company plans to grow faster than the market and achieve a minimum EBIT margin of 10 percent in the long term.

 

Drägerwerk AG & Co. KGaA

Moislinger Allee 53-55

23558 Lübeck, Deutschland

www.draeger.com  

Investor Relations:

Vanina Hoffmann

Phone:+49 451 882-2685

vanina.hoffmann@draeger.com 

Corporate Communications:

Burkard Dillig

Phone +49 451 882-2185

burkard.dillig@draeger.com 

 

Disclaimer

This press release contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date and have been prepared to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors. They entail risks and uncertainties beyond the Company's control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this report. You will find all other financial dates on our website at www.draeger.com under Investor Center/Financial Calendar.

Press release (PDF)

--- End of Message ---

Drägerwerk AG & Co. KGaA

Moislinger Allee 53-55 Lübeck Germany

Listed: Freiverkehr in Börse Stuttgart,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse,

Regulierter Markt in Bayerische Börse München,

Regulierter Markt in Börse Berlin,

Regulierter Markt in Hanseatische Wertpapierbörse zu Hamburg,

Regulierter Markt in Börse Düsseldorf,

Regulierter Markt in Niedersächsische Börse zu Hannover;

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Drägerwerk AG & Co. KGaA via Thomson Reuters ONE

HUG#1479951

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
22 nov
VWS
Hejsa Mena.  nu har jeg observeret at du kommer i meget spændende diagologer med de fleste skribente..
42
23 nov
OW
Thomas Eriksson, som er chef for investeringsbanken Carnegie, er blevet kontaktet af Finansinspektio..
34
22 nov
VWS
tauser, det korte svar er:......................................................................... ..
22
20 nov
OW
Jeg er rystet over at OW Bunkers bestyrelse er rystet.   OW Bunkers bestyrelse har i dag via Altor ..
21
26 nov
OW
  Carnegie er gå i offensiven de sidste par dage omkring deres rolle i OW Bunker sagen.  Flere medie..
20
08:47
 
Noget af det sværeste og mest risikofyldte i investeringsuniverset er at investere i turn-arounds. A..
19
26 nov
VWS
@MENA .. dit indlæg giver ikke mening i forhold til diskussionen. Men som sædvanlig kommenterer du f..
19
06:17
BAVA
Hermed mit første indlæg som nok bliver et lidt længere et af slagsen. Har fulgt Bavarian Nordic med..
15
26 nov
VWS
Du burde forvises fra dette forum. Hold kæft hvor er du trættende at høre på!! Du skal nedgøre alt o..
15
21 nov
SAS-DKK
Jeg har i de sidste par måneder kikket lidt nærmere på SAS. Årsagen til min nysgerrighed skyldes;   ..
15

Vind: Nordex henter italiensk ordre på 29 MW

27-11-2014 08:44:24
Den tyske vindmølleproducent Nordex har vundet en ordre til det italienske marked på 29 megawatt.Selskabet skal i henhold til kontrakten levere ti møller til pr..

Lundbeck/SEB: Data for nyt skizofrenimiddel er solide

26-11-2014 16:07:10
Lundbeck har stillet fase 3-data for sit nye skizofreni- og depressionsmiddel, Brexpiprazol, i udsigt under en medicinalkonference den 7-11. december, og der er..

Genmab/Jyske: Øger kursmål på potentiale i Daratumumab

26-11-2014 14:13:48
Jyske Bank ser et stort kommercielt potentiale i Genmab-stoffet Daratumumab, som for tiden testes i en stribe forsøg, der skal afdække, om midlet kan hjælpe mod..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Europa/aktier: De fleste stigninger forduftede
2
Vestas vinder ordre på 49 MW i Den Dominikanske Republik - NY
3
SAS-aktien er steget 23 pct. på en uge
4
Genmab/Jyske: Øger kursmål på potentiale i Daratumumab
5
Lundbeck/SEB: Data for nyt skizofrenimiddel er solide
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. november 2014 10:27:16
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141126.1 - EUROWEB6 - 2014-11-27 10:27:16 - 2014-11-27 10:27:16 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x